The Surgery Branch Vector Production Facility (SBVPF) was established to provide clinical-grade retroviral and lentiviral vectors to support of our gene therapy clinical trials with the goal of providing GMP quality products while reducing production time and cost. These products, both retroviral and lentiviral vectors will be used to introduce novel T cell receptors (TCR) or chimeric antigen receptors (CAR) to genetically modify naive T cells to make them specifically recognize and kill tumor. This lab provides all the clinical reagents for our clinical gene therapy program. For this report, SBVPF recently manufactured a several TCRs targeting KRAS hotspot mutations at position 12. In addition, our focus is now to isolate T cell receptors targeting nonsynonymous mutations presented by tumors from tumor infiltrating lymphocytes residing within the given tumor. Our laboratory has also provided cloning services to our group. We have constructed lentiviral vectors using gateway technology for cell reprogramming. We have also developed new clinical retroviral and lentiviral vector backbones to facilitate our clinical reagent program. We are also generating adenoviral vector constructs. My lab also developed a novel closed cell production process for specifically for our CD19 CAR clinical efforts. This new production process allows for generation of a clinical CD19 CAR cell product in 6 days and the final cell product is cryopreserved to allow flexibility in scheduling the patient's treatment. Lastly, we are testing a new hypothesis that immunogenic mutations (neoantigens) presented on a patient's tumor mediate tumor regression by TIL. In some cases, TIL cannot be generated, but TCRs can be cloned. In these instances we can use a gene therapy approach to treat patients by introducing neoantigen-specific TCRs into autologous PBMC, expanding the transduced cells ex vivo and administering to the patient. We have developed two transient vector production platforms, gammaretroviral and lentiviral, that support GMP-compliant transient vector production single patient treatments targeting neoantigens.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Scientific Cores Intramural Research (ZIC)
Project #
Application #
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Basic Sciences
Zip Code
Sabbatino, Francesco; Wang, Yangyang; Scognamiglio, Giosuè et al. (2016) Antitumor Activity of BRAF Inhibitor and IFN? Combination in BRAF-Mutant Melanoma. J Natl Cancer Inst 108:
Abate-Daga, Daniel; Lagisetty, Kiran H; Tran, Eric et al. (2014) A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer. Hum Gene Ther 25:1003-12
Rosati, Shannon F; Parkhurst, Maria R; Hong, Young et al. (2014) A novel murine T-cell receptor targeting NY-ESO-1. J Immunother 37:135-46
Feldman, Steven A; Xu, Hui; Black, Mary A et al. (2014) Use of the piggyBac transposon to create stable packaging cell lines for the production of clinical-grade self-inactivating ?-retroviral vectors. Hum Gene Ther Methods 25:253-60
Casati, Anna; Varghaei-Nahvi, Azam; Feldman, Steven Alexander et al. (2013) Clinical-scale selection and viral transduction of human naïve and central memory CD8+ T cells for adoptive cell therapy of cancer patients. Cancer Immunol Immunother 62:1563-73
Morgan, Richard A; Chinnasamy, Nachimuthu; Abate-Daga, Daniel et al. (2013) Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother 36:133-51
Zhang, Ling; Feldman, Steven A; Zheng, Zhili et al. (2012) Evaluation of ?-retroviral vectors that mediate the inducible expression of IL-12 for clinical application. J Immunother 35:430-9
Bear, Adham S; Morgan, Richard A; Cornetta, Kenneth et al. (2012) Replication-competent retroviruses in gene-modified T cells used in clinical trials: is it time to revise the testing requirements? Mol Ther 20:246-9
Morgan, Richard A; Johnson, Laura A; Davis, Jeremy L et al. (2012) Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Hum Gene Ther 23:1043-53
Yang, Shicheng; Karne, Neel K; Goff, Stephanie L et al. (2012) A simple and effective method to generate lentiviral vectors for ex vivo gene delivery to mature human peripheral blood lymphocytes. Hum Gene Ther Methods 23:73-83

Showing the most recent 10 out of 21 publications